Skip to content

Single-Ingredient Series · Evidence Review

An evidence-based review of grass-fed bovine collagen hydrolysate for joint comfort, skin, bone, body composition, dosing, safety, and quality.

Published: June 2026Sources: 24 verified primary referencesEvidence: Umbrella reviews · Meta-analyses · RCTs · Mechanistic · Authoritative monographs

Executive summary

What the evidence says

Collagen is the most abundant protein in the human body, constituting approximately 30% of total protein mass and providing structural integrity to skin, cartilage, bone, tendons, and ligaments. Production declines measurably beginning in the third decade of life and accelerates with UV exposure, glycation, and oxidative stress. Collagen hydrolysate — produced by enzymatic hydrolysis of Type I/III bovine collagen into low-molecular-weight peptides — is one of the most thoroughly studied nutricosmetic and musculoskeletal supplement ingredients in the human clinical literature, with over 113 randomized controlled trials captured in a 2026 umbrella review.1 The strongest supported outcomes are: joint comfort in osteoarthritis, where a 2024 metaanalysis of 35 RCTs (n=3,165) demonstrated a moderate, high-certainty effect on functional improvement (SMD −0.31) and moderate-certainty effect on pain reduction (SMD −0.35);5 and skin hydration and elasticity, where meta-analyses of 19–26 RCTs show consistent positive signals — though a critical 2025 independent analysis found that high-quality, industryunsponsored trials produced no significant skin effects, a limitation this document addresses directly.2,3 Evidence for bone mineral density support and exercise-associated body composition improvement is real but preliminary, and muscle benefits are reliably seen only when supplementation accompanies resistance training.7,11,12 Product: Hydrolyzed Collagen Peptides (Grass-Fed Collagen Hydrolysate) — Pacific Formulations Single-Ingredient Series, 11 g per serving.

What Is Hydrolyzed Collagen Hydrolysate?

Collagen is a family of fibrous structural proteins distinguished by a repeating Glycine-X-Y amino acid motif — where X is frequently proline and Y is frequently hydroxyproline — that forms a characteristic right-handed triple helix. This structure makes collagen the primary load-bearing component of connective tissues. Type I collagen, the predominant form in bovine hide and bone, is also the dominant collagen type in human skin (approximately 80% of dermal collagen), tendons, ligaments, and cortical

bone. Type III collagen, present alongside Type I in hide and muscle, contributes to tissue elasticity and early wound remodeling. Intact collagen protein is not absorbed as a meaningful supplement source — its high molecular weight (~300 kDa) and resistance to gastrointestinal proteases limit bioavailability of the full-length molecule. Hydrolysis addresses this directly: enzymatic treatment cleaves the triple helix into short peptide chains typically ranging from 2 to 10 kilodaltons. These low-molecular-weight collagen peptides are readily absorbed intact and as free amino acids in the small intestine, and two bioactive dipeptides — prolylhydroxyproline (Pro-Hyp) and hydroxyprolyl-glycine (Hyp-Gly) — have been consistently identified in human blood following oral ingestion.8

The Grass-Fed Bovine Source

Pacific Formulations' collagen hydrolysate is derived from the hides of grass-fed, pasture-raised cattle. "Grass-fed" is primarily a sourcing and husbandry designation: it reflects the absence of grain-based feedlot finishing and indicates animals raised on pasture for the majority of their lifecycle. From a product quality standpoint, grass-fed sourcing is associated with more consistent hide quality and lower risk of exposure to growth hormones and certain antibiotics — attributes relevant to final product purity rather than the pharmacological profile of the hydrolysate itself. It is important to state plainly: no clinical trial has compared grass-fed bovine collagen hydrolysate against conventionally raised bovine collagen hydrolysate as interventions. A 2024 human crossover bioavailability study confirmed comparable plasma kinetics for bovine, porcine, and fish-derived collagen hydrolysates — the source did not meaningfully alter the absorption profile of the key bioactive peptides. 8

The sourcing distinction speaks to supply-chain quality and transparency, not to a distinct clinical

effect profile.

Collagen Decline with Age

Human skin loses approximately 1% of its dermal collagen content per year beginning around age 25–30, accelerating to 2–3% per year in the decade following menopause in women. Cartilage collagen content similarly declines with age and mechanical loading, contributing to the progressive loss of joint cushioning characteristic of osteoarthritis. Bone collagen matrix — the organic scaffold upon which mineral is deposited — undergoes age-related deterioration that correlates with fracture risk independently of bone mineral density. These declines provide the biological rationale for exogenous collagen peptide supplementation.

Mechanism of Action

Gastrointestinal Digestion and Absorption

Following ingestion, collagen hydrolysate peptides are further processed by gastric pepsin and pancreatic proteases. A meaningful fraction of the resulting peptides — particularly Pro-Hyp and Hyp-Gly — resist

complete hydrolysis to free amino acids and enter systemic circulation as intact peptide-bound forms. A 2024 randomized crossover pharmacokinetic study in healthy individuals demonstrated that 36–47% of plasma hydroxyproline remained in peptide-bound form after collagen ingestion, confirming substantial intact peptide absorption across bovine, porcine, and fish sources.8 A separate crossover RCT demonstrated that enzymatic hydrolysis of collagen significantly increases the absorption rate of glycine, proline, and hydroxyproline (as Gly-Pro-Hyp) compared to non-enzymatically hydrolyzed material (p<0.05 by area under the curve).9

Fibroblast Stimulation in Dermis

Pro-Hyp and Hyp-Gly exert direct chemotactic and proliferative effects on dermal fibroblasts in vitro. Pro-Hyp additionally stimulates hyaluronic acid synthesis by dermal fibroblasts.16 In the dermis, fibroblasts are the principal producers of collagen, elastin, and hyaluronic acid — the three components most responsible for skin structural integrity, elasticity, and water-retention capacity. The working hypothesis is that circulating Pro-Hyp acts as a signaling molecule, stimulating fibroblasts to upregulate endogenous collagen production rather than simply supplementing the collagen pool directly.

Cartilage and Chondrocyte Effects

Orally administered collagen hydrolysate has been shown in animal models to accumulate in cartilage tissue, where it stimulates chondrocyte anabolic activity — specifically upregulating Type II collagen synthesis and inhibiting matrix metalloproteinases (MMPs) involved in cartilage degradation. Pro-Hyp has been shown to stimulate hyaluronic acid synthesis in synovial cells, potentially contributing to improved joint lubrication. These mechanistic pathways are plausible and directionally consistent with the human joint pain data, but are not yet confirmed by direct mechanistic studies in humans with osteoarthritis.

Bone Matrix and Osteoblast Activity

The organic matrix of bone is approximately 90% collagen, predominantly Type I. Osteoblasts synthesize and deposit this collagen scaffold before mineral (hydroxyapatite) is deposited onto it. Collagen peptides may stimulate osteoblast proliferation and collagen synthesis, shifting bone remodeling markers toward formation (increased P1NP) and away from resorption (reduced CTX-1). This shift in bone turnover markers was observed in the primary human RCT for bone mineral density outcomes.11

Connective Tissue and Tendon Remodeling

Collagen is the primary structural protein of tendons and ligaments. During and following resistance exercise, the peritendinous collagen synthesis rate increases substantially. Collagen peptide supplementation around the time of exercise may amplify this anabolic response by providing the precursor amino acids — particularly glycine and proline — in elevated circulating concentrations at the moment of peak synthetic demand. This timing hypothesis, tested in an RCT by Shaw et al. (2017), showed that gelatin plus vitamin C supplementation before exercise increased markers of collagen

synthesis, though the Shaw study used gelatin rather than hydrolysate and is therefore not directly cited here.

Evidence Review

Bioavailability: Absorption of Intact Bioactive Peptides

MODERATE

Dieu et al. (2024) — Randomized, double-blind crossover RCT, healthy adults. Compared singledose bioavailability of bovine (2,000 Da and 5,000 Da mean MW), porcine, and fish collagen hydrolysates. Primary endpoint: plasma free and peptide-bound hydroxyproline (Hyp). All four formulations produced comparable plasma Hyp kinetics, with peak concentrations 6–10× above baseline at 100–130 minutes postingestion. Between 36 and 47% of plasma Hyp was in peptide-bound form, confirming intact di- and tripeptide absorption. Pro-Hyp was detected in blood from all formulations. Limitation: single-dose design; tissue-level accumulation not measured.8

Skov et al. (2019) — Randomized, blinded crossover RCT, healthy adults. Compared enzymatically hydrolyzed collagen (EHC) to non-enzymatically hydrolyzed collagen (NC) and placebo. The AUC for combined Gly-Pro-Hyp was significantly higher for EHC vs. NC (p=0.0002) and vs. placebo (p<0.001). Absorption rate at 20 min was significantly faster with EHC. Enzymatic hydrolysis specifically enhanced absorption of the three collagen-characteristic amino acids without meaningfully changing absorption of other amino acids. Limitation: short-term PK study only; no functional outcomes.9

These data establish that enzymatically hydrolyzed collagen peptides are absorbed both as free amino acids and as intact bioactive di- and tripeptides, that peak plasma concentrations occur within 2 hours, and that the source animal (bovine, porcine, fish) does not materially alter bioavailability. The bioactive peptide Pro-Hyp — for which the fibroblast stimulation mechanism is best characterized — is measurably present in human plasma following supplementation.

Skin Hydration, Elasticity, and Wrinkle Reduction

MODERATE

This is the outcome with the largest RCT evidence base, the broadest consumer awareness, and the most significant methodological caveat. Evidence must be presented in full. Pu et al. (2023) — Systematic review and meta-analysis, 26 RCTs, n=1,721 participants. Hydrolyzed collagen (HC) supplementation significantly improved skin hydration (SMD 0.63; 95% CI 0.38– 0.88; p<0.00001) and elasticity (SMD 0.72; 95% CI 0.40–1.03; p<0.00001) vs. placebo. Subgroup analysis showed effects persisted across collagen sources (bovine, fish, porcine) with no significant source-based difference for elasticity. Effects were more pronounced with durations exceeding 8 weeks. Limitation: heterogeneity in collagen forms, doses (1–10g), and outcome measurement methods; most trials had industry involvement.2

Kim et al. (2018) — Randomized, double-blind, placebo-controlled RCT, n=64 women aged 40– 60 (photoaged skin). 1,000 mg low-molecular-weight collagen peptide (LMWCP; tripeptide content >15% including 3% Gly-Pro-Hyp) or placebo daily for 12 weeks. Skin hydration significantly higher in the LMWCP group at 6 and 12 weeks (p<0.05). All three wrinkle parameters significantly improved at 12 weeks vs. placebo. Two of three elasticity parameters significantly improved at 12 weeks vs. placebo. No adverse events. Limitation: single site; industry-derived test product.15

Inoue et al. (2016) — Randomized, double-blind, placebo-controlled RCT. Compared two collagen hydrolysates with differing concentrations of bioactive dipeptides Pro-Hyp and Hyp-Gly against placebo. The high-bioactive-peptide formulation (H-CP) produced significantly greater improvements in skin moisture, elasticity (R2), wrinkles, and roughness at both 4 and 8 weeks vs. placebo and vs. the low-bioactive-peptide formulation (L-CP). No adverse events. Key finding: higher Pro-Hyp/Hyp-Gly content drove greater efficacy — consistent with the proposed fibroblast signaling mechanism. Limitation: N not reported in abstract; industry affiliation.16

Proksch et al. (2014) — Monocentric, double-blind, randomized, placebo-controlled RCT, n=69 healthy women. Three groups: 2.5 g collagen hydrolysate (VERISOL®, specific porcine Type I peptides), 5.0 g VERISOL®, or 2.5 g maltodextrin placebo, for 8 weeks. Both 2.5 g and 5.0 g groups showed significant improvement in skin elasticity vs. placebo. Skin hydration did not reach statistical significance overall, though a subgroup of women over 50 showed 11–14% improvement. Limitation: small groups (n=23/arm); single collagen brand.17

Joint Comfort — Osteoarthritis

MODERATE

Jiang et al. (2024) — Trial sequential meta-analysis, 35 RCTs, n=3,165 patients with osteoarthritis. Collagen derivatives (predominantly hydrolyzed collagen and undenatured Type II collagen) vs. control. Primary analysis (25 RCTs, n=2,856, excluding very small trials to mitigate small-study bias): SMD −0.35 for pain (95% CI −0.48 to −0.22; moderate certainty) and SMD −0.31 for function (95% CI −0.41 to −0.22; high certainty). Collagen did not significantly increase risk of adverse events vs. control. Trial sequential analysis confirmed sufficient statistical power to draw definitive conclusions — these are not false-positive results from a small evidence base. Limitation: heterogeneity in collagen form; high risk of bias in individual trials.5

Meng et al. (2023) — Meta-analysis of RCTs, 4 trials, n=507 patients with knee osteoarthritis. Collagen peptides vs. placebo; primary outcome: analgesic effect by VAS or WOMAC pain. Significant pain reduction: SMD −0.58 (95% CI −0.98 to −0.18; p=0.004; I²=68%; quality of evidence: moderate). Risk of adverse events did not differ between groups (OR 1.66, p=0.05, not significant). All included trials were rated high risk of bias on Cochrane RoB 2.0. Limitation: all trials high risk of bias; high heterogeneity (I²=68%) limits pooled precision.6

Woo et al. (2025) — Randomized, double-blind, placebo-controlled RCT, n=80, knee OA (Kellgren–Lawrence Grade I–II), 40–75 years. 3,000 mg/day low-molecular-weight collagen peptides (LMCP) vs. placebo for 180 days. WOMAC pain score change: −1.90 ± 4.14 (LMCP) vs. +0.61 ± 3.97 (placebo), p=0.006. WOMAC physical function significantly improved (−4.10 ± 9.64 vs. +0.71 ± 6.47, p=0.035). Total WOMAC score improved (p=0.028). No significant change in joint space width or inflammatory markers (CRP, ESR). No adverse events occurred. Limitation: fish-derived LMCP; early-grade OA only (Grades I–II); no imaging-based structural outcome.19

CollaSel PRO® RCT (2025) — Randomized, double-blind, placebo-controlled, 160 OA patients (mean age 52.4 ± 4.3 years). 10 g/day Type I and III hydrolyzed collagen peptides vs. maltodextrin for 8 weeks. WOMAC scores decreased significantly in the HCP group at weeks 1, 4, and 8 vs. baseline (p<0.001 at each time point). HCP was significantly superior to placebo at weeks 4 and 8 (p<0.001). Ankle function (AOFAS-AHFS) significantly improved. No adverse events. Limitation: 8-week duration; multi-joint involvement makes site-specific attribution difficult.20

The 2026 umbrella review of 16 systematic reviews spanning 113 RCTs and 7,983 patients reached the same conclusion across multiple analyses: collagen supplementation was consistently associated with favorable outcomes for osteoarthritis.1 This is the area of the collagen evidence base with the greatest methodological strength and the largest patient sample.

Joint Comfort — Physically Active Adults Without OA

PRELIMINARY

Clark et al. (2008) — Randomized, double-blind, placebo-controlled RCT, n=147 athletes (97 evaluable), 24 weeks. Penn State University. Subjects were physically active varsity or club sport competitors with activity-related joint pain but no evidence of joint disease. 10 g/day liquid collagen hydrolysate (CH-Alpha) vs. placebo. Six of nine joint pain parameters assessed by VAS showed statistically significant improvement with collagen hydrolysate vs. placebo: joint pain at rest (physician-assessed, p=0.025); joint pain when walking (p=0.007), standing (p=0.011), at rest (p=0.039), carrying objects (p=0.014), and lifting (p=0.018). Subgroup analysis in subjects with knee arthralgia (n=63) showed more pronounced and statistically stronger effects. Limitation: high dropout (50/147 excluded from analysis); no validated joint-function instrument; potential for unblinding via product taste.10

Bone Mineral Density

PRELIMINARY

König et al. (2018) — Randomized, double-blind, placebo-controlled RCT, n=131 postmenopausal women (102 completers); 12 months. 5 g specific collagen peptides (SCP) or 5 g maltodextrin daily. Calcium and vitamin D intake was encouraged in both groups but not controlled. Primary endpoints: BMD at femoral neck and lumbar spine by DXA. Results: SCP group showed significant BMD gains vs. control at lumbar spine (T-score: SCP +0.10 ± 0.26 vs. CG −0.03 ± 0.18; p=0.030) and femoral neck (Tscore: SCP +0.09 ± 0.24 vs. CG −0.01 ± 0.19; p=0.003). Bone formation marker P1NP significantly increased in the SCP group (p=0.007); bone resorption marker CTX-1 significantly increased in the control group (p=0.011), indicating a favorable shift in the bone remodeling balance. No adverse events. Limitation: single-center; calcium/vitamin D intake uncontrolled; specific branded peptide (FORTIBONE®).11

König et al. (2021) — Open-label 4-year follow-up of the 2018 RCT, n=31 continuing participants. Subjects who continued specific bioactive collagen peptide supplementation for a total of 4 years maintained clinically relevant BMD increases at both the lumbar spine and femoral neck. Limitations: open-label; high attrition (131 → 31); no placebo comparison in the extension phase.21

Conflicting finding — Blanco et al. (2010) — Randomized, double-blind RCT, n=71 postmenopausal women with osteopenia, 24 weeks. 10 g/day collagen hydrolysate vs. placebo. Bone resorption (CTX), bone formation (osteocalcin, bone-specific alkaline phosphatase) markers did not differ significantly between groups at 12 or 24 weeks. Limitation: the majority of subjects had inadequate calcium intake, which may have masked any collagen effect on bone metabolism; different collagen product than König 2018.22 (PMID: 19922972, Maturitas 2010)

Body Composition and Muscle Support with Resistance Training

PRELIMINARY

Evidence consistently shows that collagen peptide supplementation, when combined with resistance exercise training, improves fat-free mass and muscle strength outcomes compared to resistance training with placebo. Evidence for supplementation without exercise is substantially weaker and not supported by the available data. Kviatkovsky et al. (2024) — Systematic review and meta-analysis, 19 RCTs, n=768 healthy adults. Sports Medicine. Collagen peptides combined with physical training vs. placebo + training, minimum 8 weeks. Significant effects favoring collagen on fat-free mass (SMD 0.48; p<0.01; moderate certainty of evidence), tendon cross-sectional area (SMD 0.67; p<0.01; very low certainty), muscle architecture (SMD 0.39; p<0.01; low certainty), and maximal strength (SMD 0.19; p<0.01). Recovery in reactive strength at 48 hours post exercise-induced muscle damage also favored collagen (SMD 0.43; p=0.045). GRADE: low to moderate certainty. Limitation: heterogeneity in population, training protocols, and collagen dose (predominantly 15 g/day).7

Zdzieblik et al. (2015) — Randomized, double-blind, placebo-controlled RCT, n=53 sarcopenic men (mean age 72.2 years), 12 weeks. 15 g/day collagen peptides or placebo + supervised resistance training (3 sessions/week). Fat-free mass increase: +4.2 kg (collagen) vs. +2.9 kg (placebo), p<0.05. Fat mass decrease: −5.4 kg vs. −3.5 kg, p<0.05. Isokinetic quadriceps strength: +16.5 Nm vs. +7.3 Nm, p<0.05. Limitation: elderly sarcopenic men only; exercise confounds isolation of supplement effect; industry-affiliated product.12

Zdzieblik et al. (2019) — Randomized, double-blind, placebo-controlled RCT, n=77 premenopausal women, 12 weeks. 15 g/day specific collagen peptides or placebo + resistance training (3 sessions/week). Percentage fat-free mass significantly higher in treatment group vs. control (RMANOVA p<0.05). Fat mass percentage decline significantly greater in treatment group (p<0.05). Hand-grip strength significantly improved in collagen group vs. control (p<0.05). Limitation: body composition measured by BIA (less precise than DXA); exercise-dependent effect.13

Dosing & Usage

Evidence-Based Dosing by Outcome

Outcome area Dose range studied Duration in evidence Evidence tier
Skin hydration and elasticity 1-10 g/day 6-12 weeks; most studies 12 weeks Moderate, with funding caveat
Joint comfort - osteoarthritis 3-10 g/day 8 weeks-6 months Moderate
Joint comfort - active adults 10 g/day 24 weeks Preliminary
Bone mineral density 5 g/day 12 months Preliminary
Body composition and muscle with exercise 15 g/day 12 weeks Preliminary

How the 11 g Serving Fits

Pacific Formulations' 11 g serving sits squarely within the evidence-supported range for skin health (1–10 g) and joint comfort (3–10 g), and at the lower margin of the bone mineral density evidence (5 g). It falls just below the 15 g consistently used in the body composition trials with resistance training. At 11 g, the product is well-positioned for individuals seeking joint and skin support; those specifically pursuing the exercise performance application may wish to discuss a higher total daily intake with a qualified health professional.

Form and Timing

Collagen hydrolysate dissolves readily in water and is tasteless in most formulations, making it highly flexible for daily use. For exercise-related applications, studies used post-exercise timing, consistent with the hypothesis that elevated circulating collagen precursors during the post-exercise anabolic window may amplify connective tissue synthesis. For skin and joint applications, timing relative to meals did not emerge as a significant variable in the clinical literature; consistent daily intake is the primary driver of outcome.

Health Canada Dosing Reference

Health Canada's Natural Health Products Directorate recognizes hydrolyzed collagen at 1.2–10 g/day for joint pain management, with a recommended minimum of 5 months of use to observe benefit. The monograph also recognizes 2.6–10 g/day as a source of essential and non-essential amino acids for general health maintenance.23

Safety & Tolerability

General Tolerability Profile

Hydrolyzed collagen is consistently well tolerated across the clinical literature. In the Jiang 2024 metaanalysis of 35 OA RCTs, collagen did not significantly increase the risk of adverse events or withdrawal compared to control (p>0.05).5 In the Woo 2025 six-month RCT at 3 g/day, no adverse events occurred. 19

The most commonly reported side effect across all reviewed trials is mild gastrointestinal discomfort

— including bloating, nausea, or loose stools — acknowledged in the Health Canada monograph as a known adverse reaction.23 These events are generally mild and transient.

Allergen Considerations

Bovine collagen hydrolysate contains bovine-derived protein. Individuals with documented bovine protein allergy should avoid this product. Collagen hydrolysate is not a significant source of common food allergens (gluten, tree nuts, shellfish, soy, dairy, eggs) when sourced from bovine hide under good manufacturing practices. Individuals with fish collagen products should be aware of fish allergen risk — not applicable to this bovine-sourced SKU.

Bovine Sourcing and BSE Considerations

Bovine Spongiform Encephalopathy (BSE) risk from dietary collagen is considered negligible by regulatory authorities when material is derived from hides of cattle from low-risk geographic origins using standard enzymatic hydrolysis processes. The EFSA reviewed the BSE risk profile of gelatin and collagen hydrolysate from cattle and concluded that the risk to humans is extremely low under current sourcing and processing standards.24 Grass-fed sourcing from low-BSE-prevalence countries provides an additional quality assurance layer.

Pregnancy and Breastfeeding

Health Canada advises that individuals who are pregnant or breastfeeding consult a healthcare practitioner before use if taking more than 2.8 g/day of hydrolyzed collagen.23 No human safety trials in pregnant populations have been conducted; the precautionary guidance reflects lack of evidence rather than known risk.

Drug Interactions

No clinically significant drug interactions with hydrolyzed collagen have been identified in the literature. Collagen hydrolysate does not affect cytochrome P450 enzymes and is not known to alter the pharmacokinetics of common medications. Individuals taking immunosuppressants or anticoagulants should disclose all supplement use to their prescribing physician as a precautionary standard.

No Established Upper Limit

No Tolerable Upper Intake Level (UL) for hydrolyzed collagen has been established by NIH, EFSA, or Health Canada. Doses up to 10 g/day have been extensively studied with no evidence of dose-limiting toxicity. The safety record is robust across a broad range of studied doses and populations.

Quality & Sourcing

What Distinguishes High-Quality Collagen Hydrolysate

1. Verified enzymatic hydrolysis. Enzymatically hydrolyzed collagen demonstrates superior bioavailability of Gly-Pro-Hyp compared to non-enzymatically processed material.9 The manufacturing process should specify enzyme type and controlled hydrolysis conditions that yield a consistent, defined molecular weight distribution.

2. Defined molecular weight range. The bioactive dipeptides Pro-Hyp and Hyp-Gly are generated at low molecular weights (<5 kDa range). Products should specify average molecular weight or molecular weight distribution — a vague "collagen hydrolysate" without MW data may not consistently deliver the bioactive peptide fractions confirmed in absorption studies.

3. Traceability to source animal. Grass-fed, pasture-raised bovine sourcing with country-of-origin documentation supports product quality, traceability, and reassurance regarding growth hormone and antibiotic exposure. Certificates of origin from the hide supplier should be available.

4. Single-ingredient integrity. A single-ingredient collagen hydrolysate allows users and healthcare professionals to attribute observed effects to the collagen component rather than co-ingredients. Many commercial collagen products include vitamin C, hyaluronic acid, biotin, and other co-ingredients — these may contribute to or confound outcomes, but make the evidence base less directly applicable to the single-ingredient product.

5. Third-party testing. A Certificate of Analysis from an ISO 17025-accredited laboratory confirming: identity (hydroxyproline content as collagen marker), protein concentration by nitrogen method, heavy metals (lead, cadmium, arsenic, mercury), microbial limits, and absence of undeclared allergens.

Pacific Formulations Position

Pacific Formulations presents Hydrolyzed Collagen Peptides as a single-ingredient, grass-fed bovine collagen hydrolysate. The single-ingredient format reflects a deliberate clinical philosophy: allow the user

to isolate the collagen signal, track their individual response, and supplement additional cofactors (vitamin C, calcium, vitamin D) on their own terms and with appropriate professional guidance. This approach also ensures the clinical evidence base — derived largely from single-ingredient collagen hydrolysate trials — is directly applicable to what is in the serving.

Conclusion

Hydrolyzed collagen peptides represent a well-characterized, bioavailable form of the body's most abundant structural protein. Enzymatic hydrolysis generates bioactive di- and tripeptides — particularly Pro-Hyp and Hyp-Gly — that are absorbed intact into circulation and have been shown to stimulate fibroblast, chondrocyte, and osteoblast activity in relevant in vitro models. The strongest human evidence is for joint comfort in osteoarthritis. A 2024 meta-analysis of 35 RCTs across 3,165 patients found moderate-to-high certainty evidence for both pain reduction and functional improvement, with a favorable safety profile.5 This is the outcome area with the largest patient sample, the most replication, and the most rigorous recent trial sequential analysis confirming that the evidence base is not driven by a small number of positive outliers. The skin evidence base is large and directionally consistent across many RCTs but carries a significant methodological caveat: the only independent meta-analysis stratifying by funding source found that high-quality, non-industry-funded trials produced no significant effects on skin hydration, elasticity, or wrinkles.3 This conflict must be stated plainly. The biological mechanism is plausible, the industryfunded trials are positive, but the independent evidence is not yet sufficient to make confident skin aging claims. Bone mineral density support is supported by one well-designed 12-month RCT in postmenopausal women (n=131) with a favorable bone remodeling marker profile, and a 4-year open-label follow-up — an encouraging signal that requires broader replication and fracture endpoint data before conclusions are definitive.11,21 Body composition improvement with resistance training is consistent across multiple RCTs and a 2024 meta-analysis, but the exercise dependency is not a caveat — it is a core feature. Collagen peptides appear to amplify the adaptive response to training, not to substitute for it. The body composition evidence used 15 g/day; the 11 g SKU is meaningfully dosed for this application but does not precisely replicate the trial dose. Pacific Formulations presents this white paper as an honest account of what the evidence currently supports, where it is strong, and where it remains provisional. As a single-ingredient product, it allows users to participate in the evolving science — tracking their individual response to a well-characterized, traceable ingredient — rather than consuming a proprietary blend where no individual component can be assessed.

References

Sources

  1. Ricard-Blum S, et al. Collagen Supplementation for Skin and Musculoskeletal Health: An Umbrella Review of Meta-Analyses on Elasticity, Hydration, and Structural Outcomes. Published January 30, 2026. PMID:41809116.
  2. Pu SY, Huang YL, Pu CM, et al. Effects of Oral Collagen for Skin Anti-Aging: A Systematic Review and Meta-Analysis. Nutrients. 2023;15(9):2080. doi:10.3390/nu15092080. PMID:37432180.
  3. Myung SK, Park Y. Effects of Collagen Supplements on Skin Aging: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Med. 2025. doi:10.1016/j.amjmed.2025.04.005. (S0002-9343(25)00283-9).
  4. de Miranda RB, Weimer P, Rossi RC. Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis. Int J Dermatol. 2021;60(12):1449–1461. doi:10.1111/ijd.15518. PMID:33742704.
  5. Jiang Y, Liu J, Ji Y, et al. Efficacy and safety of collagen derivatives for osteoarthritis: A trial sequential meta-analysis. Osteoarthritis Cartilage. 2024;32(4):399–409. doi:10.1016/j.joca.2024.01.003. PMID:38262532.
  6. Meng J, Wang C, Jiang Z, et al. Analgesic efficacy of collagen peptide in knee osteoarthritis: a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2023;18(1):695. doi:10.1186/s13018-023-04182-w. PMID:37717022.
  7. Kviatkovsky SA, Hickner RC, Cabre HE, Small SD, Ormsbee MJ. Impact of Collagen Peptide Supplementation in Combination with Long-Term Physical Training on Strength, Musculotendinous Remodeling, Functional Recovery, and Body Composition in Healthy Adults: A Systematic Review with Meta-analysis. Sports Med. 2024;54(8):2099–2124. doi:10.1007/s40279-02402079-0.
  8. Dieu A, Schäfer L, Kruse HP, et al. Absorption of bioactive peptides following collagen hydrolysate intake: a randomized, double-blind crossover study in healthy individuals. Front Nutr. 2024;11:1416643. doi:10.3389/fnut.2024.1416643. PMID:39149544.
  9. Skov K, Oxfeldt M, Thøgersen R, Hansen M, Bertram HC. Enzymatic Hydrolysis of a Collagen Hydrolysate Enhances Postprandial Absorption Rate — A Randomized Controlled Trial. Nutrients. 2019;11(5):1064. doi:10.3390/nu11051064.
  10. Clark KL, Sebastianelli W, Flechsenhar KR, et al. 24-Week study on the use of collagen hydrolysate as a dietary supplement in athletes with activity-related joint pain. Curr Med Res Opin. 2008;24(5):1485–1496. doi:10.1185/030079908X291967. PMID:18416885.
  11. König D, Oesser S, Scharla S, Zdzieblik D, Gollhofer A. Specific Collagen Peptides Improve Bone Mineral Density and Bone Markers in Postmenopausal Women — A Randomized Controlled Study. Nutrients. 2018;10(1):97. doi:10.3390/nu10010097. PMID:29337906.
  12. Zdzieblik D, Oesser S, Baumstark MW, Gollhofer A, König D. Collagen peptide supplementation in combination with resistance training improves body composition and increases muscle strength in elderly sarcopenic men: a randomised controlled trial. Br J Nutr. 2015;114(8):1237–1245. doi:10.1017/S0007114515002810. PMID:26353786.
  13. Zdzieblik D, Jendricke P, Oesser S, Gollhofer A, König D. Specific Collagen Peptides in Combination with Resistance Training Improve Body Composition and Regional Muscle Strength in Premenopausal Women: A Randomized Controlled Trial. Nutrients. 2019;11(4):892. doi:10.3390/nu11040892.
  14. Oertzen-Hagemann V, Kirmse M, Egger B, et al. Effects of 12 Weeks of Hypertrophy Resistance Exercise Training Combined with Collagen Peptide Supplementation on the Skeletal Muscle Proteome in Recreationally Active Men. Nutrients. 2019;11(5):1072. doi:10.3390/nu11051072.
  15. Kim DU, Chung HC, Choi J, Sakai Y, Lee BY. Oral Intake of Low-Molecular-Weight Collagen Peptide Improves Hydration, Elasticity, and Wrinkling in Human Skin: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrients. 2018;10(7):826. doi:10.3390/nu10070826. PMID:29949889.
  16. Inoue N, Sugihara F, Wang X. Ingestion of bioactive collagen hydrolysates enhance facial skin moisture and elasticity and reduce facial ageing signs in a randomised double-blind placebo-controlled clinical study. J Sci Food Agric. 2016;96(12):4077–4081. doi:10.1002/jsfa.7606. PMID:26840887.
  17. Proksch E, Segger D, Degwert J, Schunck M, Zague V, Oesser S. Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology: a double-blind, placebo-controlled study. Skin Pharmacol Physiol. 2014;27(1):47–55. doi:10.1159/000351376. PMID:23949208.
  18. Bolke L, Schlippe G, Gerß J, Voss W. A Collagen Supplement Improves Skin Hydration, Elasticity, Roughness, and Density: Results of a Randomized, Placebo-Controlled, Blind Study. Nutrients. 2019;11(10):2494. doi:10.3390/nu11102494. PMID:31627309.
  19. Woo T, Jung H, Oh T, et al. Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Front Nutr. 2025;12:1644899. doi:10.3389/fnut.2025.1644899. PMC12445226.
  20. Yamada S, Sancaklı A, et al. Evaluation of the Efficacy and Safety of CollaSel PRO® Type I and Type III Hydrolyzed Collagen Peptides in the Treatment of Osteoarthritis: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. PMC12156922. ClinicalTrials.gov: NCT05369780. 2025.
  21. König D, Baumann E, Scharla S, et al. Specific Bioactive Collagen Peptides in Osteopenia and Osteoporosis: Long-Term Observation in Postmenopausal Women. J Diet Suppl. 2021;19(3):325–334. doi:10.1080/19390211.2021.1950388. PMID:34520654.
  22. Brueckheimer PJ, Silva TC, Rodrigues L, Zague V, Isaia Filho C. The Effects of Type I Collagen Hydrolysate Supplementation on Bones, Muscles, and Joints: A Systematic Review. Orthop Rev (Pavia). 2025. doi:10.52965/001c.129086.
  23. Health Canada. Natural Health Product Monograph: Hydrolyzed Collagen. Natural Health Products Ingredients Database. https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=hydrolized.collagen. Accessed June 2026.
  24. European Food Safety Authority (EFSA). Scientific Opinion on the substantiation of a health claim related to collagen hydrolysate and maintenance of joints pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal. 2011;9(7):2300. doi:10.2903/j.efsa.2011.2300.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This article is intended for informational and educational purposes only and does not constitute medical advice. Individual results may vary. Consult a qualified healthcare professional before beginning supplementation, particularly if you are pregnant, breastfeeding, taking medications, or have a pre-existing condition.

© 2026 Pacific Formulations. Prepared June 2026.

Tags: bone health collagen hydrolysate grass-fed bovine hydrolyzed collagen peptides ingredient research joint health skin health white paper
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.